Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced NET of GI or lung origin
NCT01524783Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of everolimus in Gastrointestinal neuroendocrine tumor, Lung Neuroendocrine Tumor, sponsored by Novartis. Started Mar 2012; status: completed.
02
Drugs
everolimus
03
Conditions
Gastrointestinal neuroendocrine tumorLung Neuroendocrine Tumor
Beyond the preview
Go deeper on NCT01524783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524783.